BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Sep 13, 2010
 |  BC Week In Review  |  Company News  |  Deals

reMYND, Roche deal

The partners will develop two of reMYND's preclinical programs to treat Parkinson's disease and Alzheimer's disease. The programs consist of small molecules against undisclosed targets that prevent alpha-synuclein (

Read the full 128 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >